China Resources Pharmaceutical completes second tranche bond issuance

China Resources Pharmaceutical Group Limited announced the completion of the public issuance of its second tranche of 2025 Corporate Bonds in the PRC. The issuance, carried out by CR Pharmaceutical Holdings, a wholly-owned subsidiary, raised an aggregate principal amount of 1.1 bn yuan. These bonds have a term of three years and carry a coupon rate of 1.78% per annum.

The net proceeds from this issuance are earmarked for a variety of strategic uses. These include funding production expenditures, repaying corporate debts, and replenishing working capital. The funds will also support project development and operation expenditures, as well as investments related to scientific and technological innovations, all in compliance with applicable laws and regulations.

Shareholders and potential investors of China Resources Pharmaceutical Group Limited are advised to exercise caution when dealing in the company's securities. The board of directors includes Mr. Bai Xiaosong as chairman.